ReviewMedicine2020
Primary hepatoid carcinoma of the ovary: A case report and review of the literature.
Review in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Imaging of pancreatic hepatoid adenocarcinoma: a scoping review.Quantitative imaging in medicine and surgery · 2026Review
- Spontaneous rupture of hepatic metastasis as the initial presentation of gastric hepatoid adenocarcinoma: a rare case report and literature review.Frontiers in oncology · 2026Article
- Hepatoid carcinoma of the ovary: a literature review.Frontiers in oncology · 2026Review
- Hepatoid Carcinoma of the Ovary: Case Report, Clinical Management, and Insights From Literature Review.Clinical case reports · 2025Article
- A case of complete response to radiotherapy combined with durvalumab and tremelimumab in a patient with unknown primary hepatocellular carcinoma arising in the lumbar spine.Clinical journal of gastroenterology · 2025Article
- Case Report: A rare case of hepatoid carcinoma of the ovary with genomic profiling and long-term follow-up: diagnostic and therapeutic perspectives.Frontiers in oncology · 2025Article
- [Primary uterine hepatoid adenocarcinoma: Clinicopathological analysis of 2 cases and literature review].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Review
- A pancreatic adenocarcinoma mimicking hepatoid carcinoma of uncertain histogenesis: A case report and literature review.Oncology letters · 2023Article
- A 47-year-old female with primary hepatoid adenocarcinoma in the pelvic retroperitoneum.Quantitative imaging in medicine and surgery · 2023Article
- A Rare Case of Hepatocellular Carcinoma Recurrence in Ovarian Site after 12 Years Mimicking a Hepatoid Adenocarcinoma: Case Report.Journal of clinical medicine · 2023Article
- Genomic profiling and the impact of MUC19 mutation in hepatoid adenocarcinoma of the stomach.Cancer communications (London, England) · 2022Article
- Case Report: A Rare Case of Hepatoid Adenocarcinoma in Stomach and Duodenum Simultaneously.Cancer management and research · 2022Article
- Extra-Hepatic Hepatoid Carcinomas in Female Reproductive System: Three Case-Reports with a Literature Review.Cancer management and research · 2021Article
- Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHepatoid carcinoma of the ovary (HCO) is a rare disease that originates from the ovarian surface epithelium. It is histologically characterized as hepatocellular carcinoma (HCC) with a hepatocyte-rich granular cytoplasm. PATIENT CONCERNS: A 65-year-old female patient was admitted with complaints of indigestion, abdominal bloating, and pain. DIAGNOSIS: The patient showed an elevated level of serum alpha-fetoprotein (AFP) with abdominal bloating and pain. After surgery and histopathology analysis, she was finally diagnosed with HCO, Figo stage IC.
interventionsAfter cytoreductive surgery, she underwent adjuvant chemotherapy with carboplatin and paclitaxel. Although the disease was diagnosed at an early stage, it recurred 6 months after completion of adjuvant chemotherapy. Elevation of serum AFP level and removal of a mass from the lumbar vertebra confirmed the recurrence of this disease. Subsequently, the patient underwent radiation therapy and palliative chemotherapy. OUTCOMES: She died 31 months after the diagnosis due to disease progression.
conclusionThe aggressive nature of HCO was clearly observed in this case despite early diagnosis and treatment. Further studies are needed to understand the proper treatment and prognostic factors of HCO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.